JAK1 and glioblastoma: We used the JAK1/3 inhibitor tofacitinib and STAT3 inhibitor S3I‐201 to assess the involvement of the JAK3‐STAT3 signaling pathway in the CTRP8‐mediated enhanced motility of GBM using real‐time migration assays.